Literature DB >> 22118716

Type-specific prevalence of Human Papillomavirus infection among women in the Northwest Territories, Canada.

Y Jiang1, P Brassard, A Severini, V Goleski, M Santos, A Leamon, S Chatwood, C Lys, G Johnson, T Wong, A Kotaska, K Kandola, Y Mao.   

Abstract

BACKGROUND: Certain types of Human Papillomavirus (HPV) are highly associated with cervical cancer and precursor lesions (dysplasia), but the distribution of HPVs in Northern Canada is largely unknown. This study determined the prevalences of HPV infection due to different virus types and the association of different virus types with cervical dysplasia in the Northwest Territories (NWT).
METHODS: Between April 2008 and March 2009, women who underwent routine Pap testing in the NWT were included in the study. An in-house Luminex assay detected type-specific HPV infections. The HPV prevalence rates and population attributable risk fractions were calculated.
RESULTS: In 5725 bio-samples, the overall HPV prevalence was 24.2%, and of the HPV-positive samples, 76.6% harbored high-risk types, 35.2% harbored multi-type infections, and 21.6% harbored HPV16 or 18 infections. The HPV prevalence was approximately 50% higher among Aboriginal than non-Aboriginal women. The age-specific HPV prevalence exhibited a U-shape distribution in the Aboriginal group. The prevalence of HPV16 or 18 infections found in high-grade lesions was 34.1%. Among this study population, 89.5% of the cases with cervical dysplasia were attributable to HPV infection, with 27.1% attributable to HPV16/18.
CONCLUSION: The high prevalence of high-risk HPV in this population, particularly in the Aboriginal group, will require further studies to identify specific predictors of infection. Crown
Copyright © 2011. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118716     DOI: 10.1016/j.jiph.2011.09.006

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  6 in total

1.  Evaluation of using composite HPV genotyping assay results to monitor human papillomavirus infection burden through simulation.

Authors:  Carol Y Lin
Journal:  BMC Infect Dis       Date:  2015-03-12       Impact factor: 3.090

Review 2.  Barriers, supports, and effective interventions for uptake of human papillomavirus- and other vaccines within global and Canadian Indigenous peoples: a systematic review protocol.

Authors:  Kelly J Mrklas; Shannon MacDonald; Melissa A Shea-Budgell; Nancy Bedingfield; Heather Ganshorn; Sarah Glaze; Lea Bill; Bonnie Healy; Chyloe Healy; Juliet Guichon; Amy Colquhoun; Christopher Bell; Ruth Richardson; Rita Henderson; James Kellner; Cheryl Barnabe; Robert A Bednarczyk; Angeline Letendre; Gregg S Nelson
Journal:  Syst Rev       Date:  2018-03-02

3.  Type-specific human papillomavirus infections and Pap test findings in Inuit and non-Inuit women in Nunavut, Canada.

Authors:  S Totten; A Severini; G C Jayaraman; S T Faybush; G Johnson; A A Demers; I Sobol; Y Mao; T Wong
Journal:  Can Commun Dis Rep       Date:  2015-03-05

4.  The Arctic Human Health Initiative: a legacy of the International Polar Year 2007-2009.

Authors:  Alan J Parkinson
Journal:  Int J Circumpolar Health       Date:  2013-08-05       Impact factor: 1.228

5.  Type-specific prevalence of human papillomavirus in women screened for cervical cancer in Labrador, Canada.

Authors:  Alberto Severini; Ying Jiang; Paul Brassard; Howard Morrison; Alain A Demers; Elizabeth Oguntuase; Muna Al-Rushdi; Felicia Preston; Samuel Ratnam; Yang Mao
Journal:  Int J Circumpolar Health       Date:  2013-02-21       Impact factor: 1.228

6.  The prevalence of human papillomavirus and its impact on cervical dysplasia in Northern Canada.

Authors:  Ying Jiang; Paul Brassard; Alberto Severini; Yang Mao; Y Anita Li; Julie Laroche; Susan Chatwood; Andre Corriveau; Kami Kandola; Brendan Hanley; Isaac Sobol; Muna Ar-Rushdi; Gordon Johnson; Jane Lo; Sam Ratnam; Tom Wong; Alain Demers; Gayatri Jayaraman; Stephanie Totten; Howard Morrison
Journal:  Infect Agent Cancer       Date:  2013-07-01       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.